Biomedical Management of Autism: What Works? Core Features of Autism. Biomedical Management of Autism: What Works?
|
|
- Emory Stafford
- 6 years ago
- Views:
Transcription
1 Biomedical Management of Autism: What Works? 8th Annual Developmental Disabilities: An Update for Health Professionals University of California, San Francisco Heidi Feldman, MD, PhD Lynne C. Huffman, MD Stanford University Department of Pediatrics Biomedical Management of Autism: What Works? Overview Clinical scenario (Dr. Feldman) al and Complementary-Alternative Medical (CAM) treatments (Dr. Huffman) Rationale and methods of comprehensive literature review Study quality and strength of evidence Questions and Discussion (Drs. Feldman and Huffman) Medical Management of Autism: What Works? Learning Objectives Participants will understand the scope of scientific evidence concerning pharmacologic and CAM treatments for autism Participants will be able to use scientific studies to support their thinking and decisionmaking about clinical issues Core Features of Autism Qualitative impairment of social interaction Impairment in eye-to-eye gaze, gestures Lack of social reciprocity Qualitative impairment of communication Delay in development of spoken language Idiosyncratic vocalization Restricted and repetitive behaviors Repetitive mannerisms Persistent preoccupation with parts of objects
2 Associated Symptoms Behavior problems Aggression and oppositionality Hyperactivity Self-injury Dysregulation Irritability Emotional lability Depression and anxiety Odd responses to sensory stimuli Eating abnormalities Sleep problems GI disturbances Increasing Number of Reported Cases Studies over past decade 2-5 cases autism/10,000 (Bryson, 1997) 66 cases of ASD/10,000 (~1/150 children) (CDC, 2007) Current Treatment Options Goals of treatment Increase quality of life and functional independence Lessen associated deficits and family distress Mainstays of treatment Behavior management Intensive, sustained special education Limitations of behavior management and education Slow progress Labor intensive, expensive Difficult to take to scale Appeal of medication as adjunct treatment Use of Medications and CAM in Children with ASD is Increasing 52-57% taking psychotropic/ antiepileptic drugs Aman, et al. (2003) Oswald and Sonankar (2007) 32-74% using CAM Levy, et al. (2003) Hanson, et al. (2007)
3 Issues in Choosing Medication Determining effectiveness Choice of target symptoms: core or associated Short versus long-term effects Balance between benefits and adverse effects Documenting change Target symptoms vary across children Variability within a child over time Current Status of the Field Many pharmacologic and CAM treatments have been proposed or tried There is one treatment that is FDA-approved for children with autism (risperidone) Some treatments have supporting scientific studies that demonstrate effectiveness for autism symptoms Some innovative treatment strategies reflect emerging scientific evidence Some treatments have scientific studies that demonstrate lack of effectiveness For many treatments, few or no studies Current Status of the Field Beneficial effect or lack of effect? How can we determine which treatment fits in which category? We can begin with a systematic review of scientific literature. Comprehensive Review: Rationale Integrate existing information and support decision making Separate insignificant literature from salient studies Establish scientific consistency and generalizability Increase power and precision of estimates of treatment effects and exposure risks Limit bias and improve reliability/accuracy of conclusions
4 Research Questions How effective are pharmacologic and CAM interventions for children with ASD? Which interventions are useful for core symptoms of autism? Which interventions are useful for associated symptoms? What are adverse effects of medication? Approach Utilize stringent methodology Complete comprehensive search, applying clear inclusion/exclusion criteria to identified articles Review each study (2 independent reviewers) and assign quality rating (Scientific Merit Rating Scale score) Group studies by treatment and establish strength of evidence Develop evidence-based recommendations Quality: Scientific Merit Rating Scale (SMRS) Scores Merit rating based on weighted domains Design (.30) Measurement of treatment effect/outcome (.30) Participant ascertainment (.15) Measurement of treatment (.15) Generalization of treatment effect (.10) SMRS score Very Poor Poor Weak Adequate Sound Rigorous Articles Identified in Search 85 Treatments 112 Articles Included in Review 27 CAM Treatments 841 Articles Identified as Potentially Relevant 114 Behavioral/Educational 729 Articles Excluded from Review CAM
5 Included Medications 85 Articles on Medication Included CAM Treatment 27 Articles on CAM Treatment 29 Antipsychotic (Atypical) 15 Peptide Hormone 6 Dietary supplement: Vitamin 5 Dietary supplement: Protein/Amino Acid 11 Anti-depressant 7 Psychostimulant 1 Dietary supplement: Mineral 2 Dietary supplement: Hormone 7 Opioid antagonist 5 Anti-epileptic (Mood Stabilizer) 1 Dietary supplement: Digestive Enzymes 2 Dietary supplement: Fatty Acid 5 Anti-infective 3 Autonomic (Anti-Alzheimer) 6 Modified Diet 2 Neurofeedback 2 Anti-histamine 1 Anxiolytic Chelator 1 Oxygen Acceptable Evidence I Strongest Acceptable Evidence II Strong Insufficient Evidence I Early Investigation Insufficient Evidence II Unestablished Discredited Treatment I: Ineffective Discredited treatment II: Harmful Strength of Evidence Multiple acceptable studies (SMRS=5 or 4) with beneficial effects Multiple minimally acceptable studies (SMRS=3) with beneficial effects Few weaker studies (SMRS=2) with beneficial effects Very poorly controlled studies (SMRS=1 or 0) with beneficial effects OR Poorly controlled studies (SMRS=2, 1, or 0) with no beneficial effects or mixed effects or adverse effects Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with no beneficial effects Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with adverse effects and CAM: What Works? Acceptable evidence supporting clinical recommendations (Strongest/Strong) Core symptoms Associated symptoms Behavior problems Regulatory problems Insufficient evidence (Early Investigation/Unestablished) Discredited Treatment (Ineffective/Harmful)
6 Acceptable Evidence: ASD Core Symptoms Global Impaired social interaction Impaired communication Restricted repetitive behavior Strongest (atypical antipsychotic) Naltrexone (anti-opioid) Strong Atomoxetine/Tianeptine (anti-depressant, other) Escitalopram/Fluoxetine (anti-depressant, SSRI) Acceptable Evidence: ASD Behavior Problems General Hyperactivity Self-injury Aggression and oppositionality Strongest Methylphenidate (psychostimulant) Methylphenidate Strong Atomoxetine/Tianeptine Naltrexone Strongest = At least 2 acceptablestudies (SMRS=5 or 4) with beneficial effects Strongest = At least 2 acceptablestudies (SMRS=5 or 4) with beneficial effects Strong = At least 2 minimally acceptablestudies (SMRS=3) with beneficial effects Strong = At least 2 minimally acceptablestudies (SMRS=3) with beneficial effects Acceptable Evidence: ASD Regulatory Problems Strongest Strong Irritability/Anger Naltrexone Discredited Treatment: ASD Core Symptoms Ineffective Harmful Global Methylphenidate Emotional Lability Depression/Anxiety Sensory Abnormalities/ Self-stimulation Eating Problems Sleeping Problems GI Problems Methylphenidate Impaired social interaction Impaired communication Restricted repetitive behavior Ineffective = Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with no beneficial effects Strongest = At least 2 acceptablestudies (SMRS=5 or 4) with beneficial effects Harmful = Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with adverse effects Strong = At least 2 minimally acceptablestudies (SMRS=3) with beneficial effects
7 Discredited Treatment: ASD Behavior Problems Discredited Treatment: ASD Regulatory Problems General Hyperactivity Aggression/ Oppositionality Self-injury DT/Ineffective DT/Harmful Irritability/Anger Emotional Lability Depression/Anxiety Sensory Abnormalities/ Self-stimulation Eating Problems Sleeping Problems GI Problems DT/Ineffective DT/Harmful Ineffective = Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with no beneficial effects Harmful = Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with adverse effects Ineffective = Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with no beneficial effects Harmful = Multiple acceptable/minimally acceptable studies (SMRS=5, 4, or 3) with adverse effects Insufficient Evidence 1: Early Investigation Type and Class Autonomic (Anti-Alzheimer) Anti-depressant (SNRI; TCA) Autonomic (Anti-hypertensive) Anti-infective (Anti-microbial) Anti-infective (Anti-TB) Medications Galantamine Rivastigmine Venlafaxine Clomipramine Clonidine Guanfacine Propanolol Vancomycin Cycloserine Target Symptom Core symptoms; Impaired cognition Aggression Irritability Aggression; self-injury; hyperactivity Irritability Hyperactivity; self-injury Irritability; sleep problems Core symptoms Anxiolytic Buspirone Core symptoms Irritability Anti-infective (Immune enhancer) Immunoglobulin Core symptoms Hyperactivity GI symptoms Insufficient Evidence 1: Early Investigation CAM Type CAM Treatments Target Symptom Dietary supplement Dietary supplement Hormones -Melatonin Proteins/Amino Acids -Carnosine -Dimethylglycine (DMG) -Tetrahydrobiopterin (BH4) Sleep problems Core symptoms Impaired social interaction Dietary supplement Multi-vitamins Sleep problems; GI Problems Modified diet Gluten-free/Casein-free Depression/anxiety Oxygen Hyperbaric oxygen Core symptoms Impaired social interaction Mineral salt (Mood stabilizer) Lithium Aggression Irritability; emotional lability Early Investigation = Few weaker studies (SMRS=2) Early Investigation = Few weaker studies (SMRS=2) with beneficial effects with beneficial effects
8 Insufficient Evidence 2: Unestablished Type and Class Medications Target Symptom Anti-infective (Anti-viral) Amantadine Behavior problem Regulatory problem Autonomic (Anti-Alzheimer) Memantine Behavior problem Regulatory problem Anti-depressant (SSRI) Fluvoxamine Core symptom Anti-depressant (NaSSA) Mirtazapine Behavior problem Regulatory problem Anti-epileptic (Mood stabilizer) Lamotrigine Levetiracetam Topiramate Valproate Behavior problem Regulatory problem Peptide Hormones ACTH analog Core symptoms Behavior problem Unestablished = Very poorly controlled studies (SMRS=1 or 0) with beneficial effects OR Poorly controlled studies (SMRS=2, 1, or 0) with no beneficial effects or mixed effects or adverse effects Insufficient Evidence 2: CAM Type CAM Treatments Target Symptoms Chelators Dimercaptosuccinic acid (DMSA) Core symptoms Dietary supplements Modified diets Digestive enzymes Fatty acids (fish oil, flaxseed oil) Minerals (magnesium, iron) Ketogenic Allergen-free Behavior problems Regulatory problems Core symptoms Behavior problems Regulatory problems Neurofeedback EEG biofeedback Core symptoms Behavior problems Immune enhancement Anti-fungal agents Colostrum Enzyme-potentiated desensitization Colloidal silver Garlic oil Probiotics Behavior problems Regulatory problems Behavior problems Regulatory problems Unestablished = Very poorly controlled studies (SMRS=1 or 0) with beneficial effects OR Poorly controlled studies (SMRS=2, 1, or 0) with no beneficial effects or mixed effects or adverse effects Summary: Medications and other atypical antipsychotics Acceptable evidence of benefit Improving core symptoms Decreasing behavior problems (hyperactivity, aggression) Decreasing regulatory problems (irritability) Adverse effects very common and limiting Somnolence Rhinitis, respiratory symptoms, dry mouth Increased appetite, unacceptable weight gain Naltrexone Acceptable evidence of benefit Improving core symptoms (general) Decreasing behavior problems (hyperactivity) Decreasing regulatory problems (irritability) Adverse effects Sedation Bitter taste, but patch now available and unstudied Summary: Medications Anti-depressants (SSRI) Acceptable evidence of benefit Improving core symptoms (repetitive behavior) Adverse effects Sedation Dry mouth, constipation Black box notice suicidality Anti-depressants (Other Atomoxetine, Tianeptine) Acceptable evidence of benefit Improving core symptoms (impaired social interaction) Decreasing behavior problems (hyperactivity) Adverse effects Sedation Loss of appetite Black box notice - suicidality
9 Summary: Medications Methylphenidate Acceptable evidence of benefit Decreasing behavior problems (hyperactivity, aggression) Decreasing regulatory problems (irritability) Adverse effects Nervousness, insomnia Increased heart rate and blood pressure Loss of appetite Summary: CAM Treatments No published study of CAM treatments met criteria for acceptable evidence demonstrating beneficial effect Conclusion Given rising numbers of documented autism, severity of symptoms, and frequency of pharmacologic medication/cam use, there is a notable lack of research Research Issues Randomized controlled trials: large samples with baseline measures Mixed interventions: behavioral + pharmacologic Practice-based evidence: using single-subject design methodology Collaboration of parents, child, and clinicians, with input from educators and therapists Specification of target outcomes and time frame Careful monitoring of effectiveness in multiple settings
10 Clinical Issues Use of single-subject design methodology Collaboration of parents and child, with input from educators and therapists Be willing to discontinue medication or CAM if not effective Minimize poly-pharmacy Reconsider medication at different developmental stages Project Background Stanford research team Lynne Huffman, MD, Principal Investigator Trenna Sutcliffe, MD, MSc Ima Tanner, BA Heidi Feldman, MD, PhD CA Department of Developmental Services and Napa County Office of Education Autistic Spectrum Disorders: Guidelines for Effective Interventions Project (2005) Systematic literature reviews and documentation Behavioral/educational interventions /CAM interventions : planned public release of information Reflections and Questions 10
Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationAutism/Pervasive Developmental Disorders Update. Kimberly Macferran, MD Pediatric Subspecialty for the Primary Care Provider December 2, 2011
Autism/Pervasive Developmental Disorders Update Kimberly Macferran, MD Pediatric Subspecialty for the Primary Care Provider December 2, 2011 Overview Diagnostic criteria for autism spectrum disorders Screening/referral
More informationTools that make a difference in mental health symptoms of autistic spectrum children Sumru Bilge-Johnson M.D. Program Director of Child Psychiatry
Tools that make a difference in mental health symptoms of autistic spectrum children Sumru Bilge-Johnson M.D. Program Director of Child Psychiatry Fellowship Associate Professor, Child Psychiatry NEOMED
More information10/3/2016. Disclaimer. What is Autism? Autistic Behaviors
A novel evidence based ranking scale for medications and supplements in autism spectrum disorders Dan Rossignol MD FAAFP Rossignol Medical Center Florida Office (Melbourne, FL): 321.259.7111 California
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationInterventions for Autism: Translating Research into Practice
Interventions for Autism: Translating Research into Practice Cindy Canceko Llego, MD, MSc Developmental-Behavioral Pediatrician Clinical Epidemiologist Objectives To discuss the importance of good scientific
More informationTreatment of Autism Spectrum Disorder in Children and Adolescents
Evidence-Based Medicine Key Words: autism spectrum disorder, treatment, psychotherapy, psychopharmacology Treatment of Autism Spectrum Disorder in Children and Adolescents By Melissa DeFilippis, Karen
More informationAn Overview on the Use of Psychotropic Medications
An Overview on the Use of Psychotropic Medications Marilyn B. Benoit, M.D. Chief Clinical Officer SVP, Clinical & Professional Affairs Classes of Medications Antidepressants Anti-anxiety Mood stabilizers
More informationChallenging ASD Cases November 11, Melanie Penner, MD, MSc, Mohammad Zubairi, MD, MEd,
Challenging ASD Cases November 11, 2017 Melanie Penner, MD, MSc, FRCPC @drmelpenner Mohammad Zubairi, MD, MEd, FRCPC @md_mszubairi Learning Objectives By the end of this workshop, participants will: 1)
More informationAn Autism Primer for the PCP: What to Expect, When to Refer
An Autism Primer for the PCP: What to Expect, When to Refer Webinar November 9, 2016 John P. Pelegano MD Chief of Pediatrics Hospital for Special Care Disclosures None I will not be discussing any treatments,
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationAutism: Practical Tips for Family Physicians
Autism: Practical Tips for Family Physicians Keyvan Hadad, MD, MHSc, FRCPC Alberta College of Family Physicians 61st Annual Scientific Assembly March 5, 2016 No conflict of interest Diagnosis and Misdiagnosis
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More information6/22/2012. Co-morbidity - when two or more conditions occur together. The two conditions may or may not be causally related.
Autism Spectrum Disorders and Co-existing Mental Health Issues By Dr. Karen Berkman Objective To present an overview of common psychiatric conditions that occur in persons with autism spectrum disorders
More informationEffective Health Care Program
Comparative Effectiveness Review Number 189 Effective Health Care Program Medical Therapies for Children With Autism Spectrum Disorder An Update Executive Summary Introduction Autism spectrum disorder
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder
Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM
Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More informationMedications in Autism: What We Know and Don't Know
Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental
More informationAutism: Treatment Trends
Lewis County Autism Coalition Friday, November 2 nd, 2012 Autism: Treatment Trends Glenn C. Tripp, M.D. Developmental Behavioral Pediatrics Medical Director, Developmental Services Mary Bridge Children
More informationAutism and Pervasive Developmental Disorders (PDD) # 01072
Autism and Pervasive Developmental Disorders (PDD) # 01072 What is it? Diagnoses Codes 299.0 299.91 CPT Codes G0151, G0153, H0032, H2019, H2021, S9128, 82136, 82139, 83655, 88245 88264, 90804 90809, 90810
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice 1 Guideline title SCOPE Autism: the management and support of children and young people on the autism spectrum 1.1 Short
More informationAlpha-2 Agonists. Antipsychotics
Table 5: Randomized Controlled Trials of Psychotropic Medications in Children and Adolescents with ASD Agent Study Target Symptoms Dose Demographics Significant Side Clonidine Guanfacine Jaselskis et al.,
More informationOptions for Medication Management: Rx and OTC/Natural Treatments AMY NEWMEYER MD CHKD DIVISION OF DEVELOPMENTAL PEDIATRICS MARCH 24, 2018.
Options for Medication Management: Rx and OTC/Natural Treatments AMY NEWMEYER MD CHKD DIVISION OF DEVELOPMENTAL PEDIATRICS MARCH 24, 2018 Disclosures I have no conflicts of interest to disclose 1 Objectives
More informationComplementary and alternative treatments
Complementary and alternative treatments Evdokia Anagnostou, MD Clinician Scientist, Bloorview Research Institute Associate Professor, Department of Pediatrics, University of Toronto Disclosures Consulting:
More informationAutism Spectrum Disorder: A Primer for PCPs
Autism Spectrum Disorder: A Primer for PCPs Learning Objectives 1. Define current ASD diagnostic criteria 2. Identify ASD screening tools, including the M-CHAT-R/F 3. Describe treatments/interventions
More informationTo Give or not to Give Medication: That is the Question
To Give or not to Give Medication: That is the Question Charmi Patel Rao, MD September 14, 2018 Introduction Board Certified Child & Adolescent Psychiatrist Clinical expertise in ECMH and Developmental
More informationHealth Care for People of all ages with Autism. Karen Ratliff-Schaub, M.D. Associate Professor, Clinical Pediatrics, Ohio State University
Health Care for People of all ages with Autism Karen Ratliff-Schaub, M.D. Associate Professor, Clinical Pediatrics, Ohio State University Overview DSM-5 Autism Spectrum Disorders Incidence Causes of ASD
More informationJennifer Zarcone. Kennedy Krieger Institute and Johns Hopkins School of Medicine
Jennifer Zarcone Kennedy Krieger Institute and Johns Hopkins School of Medicine 1 2 Estimated that between 20% to 45% of people with autism and ID are taking psychotropic medication 14% 30% are taking
More informationFact Sheet 8. DSM-5 and Autism Spectrum Disorder
Fact Sheet 8 DSM-5 and Autism Spectrum Disorder A diagnosis of autism is made on the basis of observed behaviour. There are no blood tests, no single defining symptom and no physical characteristics that
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationPsychopharmacology of Autism Spectrum Disorder
Psychopharmacology of Autism Spectrum Disorder Christopher J. McDougle, MD Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral Hospital
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationPaediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK).
Paediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK). Childhood pharmacokinetics Children have greater hepatic capacity More glomerular filtration Less fatty tissue Less ability to store
More informationTherapies for Children With Autism Spectrum Disorders. A Review of the Research for Parents and Caregivers
Therapies for Children With Autism Spectrum Disorders A Review of the Research for Parents and Caregivers Is This Guide Right for the Child in My Care? Yes, if: The child you care for is between 2 and
More informationDevelopmental Disorders also known as Autism Spectrum Disorders. Dr. Deborah Marks
Pervasive Developmental Disorders also known as Autism Spectrum Disorders Dr. Deborah Marks Pervasive Developmental Disorders Autistic Disorder ( Autism) - Kanner Asperger Syndrome Pervasive Developmental
More informationPsychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson
Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric
More informationThis guideline has not undergone previous surveillance.
Surveillance report 2016 Autism spectrum disorder in under 19s: support and management National Institute for Health and Care Excellence Surveillance programme Surveillance proposal consultation document
More informationWhat About Health 3: Challenging Behaviors
The title of this presentation is What About Health. I m. In this presentation I will discuss a number of health and mental health issues related to children with ASD. 1 Now I am going to switch to discussing
More informationMedication use tendencies
Health Promoting psychotropic medication use in persons with autism Ruth Myers MD ruthmmyers@yahoo.com Medication use tendencies Large quantities of unmonitored supplements Medications used in ways they
More informationFrom Diagnostic and Statistical Manual of Mental Disorders: DSM IV
From Diagnostic and Statistical Manual of Mental Disorders: DSM IV (I) A total of six (or more) items from (A), (B), and (C), with at least two from (A), and one each from (B) and (C) (A) qualitative impairment
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationDSM-IV Criteria. (1) qualitative impairment in social interaction, as manifested by at least two of the following:
DSM-IV Criteria Autistic Disorder A. A total of six (or more) items from (1), (2), and (3), with at least two from (1), and one each from (2) and (3): (1) qualitative impairment in social interaction,
More informationCase Study 2/16/11. Gary Stobbe, MD
Gary Stobbe, MD Clinical Assistant Professor University of Washington Attending Neurologist Seattle Children s Autism Center Can be defined as any agent or therapy that directly influences the body s internal
More informationJessica A. Hellings, MD, MB.BCh., M.Med Psych.
Autism Spectrum Disorders Jessica A. Hellings, MD, MB.BCh., M.Med Psych. Director Neurodevelopmental Psychiatry Study Program The Ohio State University Nisonger Center The Ohio State University Wexner
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationAutism Spectrum Disorder What is it?
Autism Spectrum Disorder What is it? Robin K. Blitz, MD Resident Autism Diagnostic Clinic Lecture Series #1 Learning Objectives What can we talk about in 20 minutes? What is Autism? What are the Autism
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationCLINICAL CRITERIA FOR UM DECISIONS Applied Behavior Analysis (ABA) Services
COMMERCIAL CLINICAL CRITERIA FOR UM DECISIONS Applied Behavior Analysis (ABA) Services Capital Health Plan (CHP) utilizes medical coverage guidelines to review and make benefit and/or medical necessity
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationDisclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013
A Rational Approach to Psychopharmacology Disclosure Statement Full time employed physician with MaineGeneral Medical Center in Waterville and Augusta No conflicts of interest to disclose Goals Promote
More informationBrief Notes on the Mental Health of Children and Adolescents
Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationBrainwave The Irish Epilepsy Association
249 Crumlin Road Dublin 12 Tel: 01-4557500 Email: info@epilepsy.ie Web: www.epilepsy.ie AUTISTIC SPECTRUM DISORDER (ASD) AND EPILEPSY Rates of epilepsy among children and adults with autism may be higher
More informationINFORMATION PAPER: INTRODUCING THE NEW DSM-5 DIAGNOSTIC CRITERIA FOR AUTISM SPECTRUM DISORDER
INFORMATION PAPER: INTRODUCING THE NEW DSM-5 DIAGNOSTIC CRITERIA FOR AUTISM SPECTRUM DISORDER What is the DSM-5? The Diagnostic and Statistical Manual of Mental Disorders (the DSM) is developed by the
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More information11/2/2016 INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM FACULTY DISCLOSURE
FACULTY DISCLOSURE INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM KristinDawson, MD Assistant Professor University of Kentucky No commercial conflicts of Interest Salary
More informationAutism Spectrum Disorder What is it?
Autism Spectrum Disorder What is it? Robin K. Blitz, MD Director, Developmental Pediatrics Resident Autism Diagnostic Clinic Lecture Series #1 Learning Objectives What can we talk about in 20 minutes?
More information6/5/2018 SYLVIA J. ACOSTA, PHD
SYLVIA J. ACOSTA, PHD ASSOCIATE PROFESSOR SUMMER INSTITUTE JUNE 1 Introduction to Autism Spectrum Disorder (ASD) for Educators JUNE 15, 2018 2 Objectives Participants will: Identify the 2 diagnostic categories
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAutism Spectrum Disorder What is it? Robin K. Blitz, MD Resident Autism Diagnostic Clinic Lecture Series #1
Autism Spectrum Disorder What is it? Robin K. Blitz, MD Resident Autism Diagnostic Clinic Lecture Series #1 Learning Objectives What can we talk about in 20 minutes? What is Autism? What are the Autism
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationTherapies for Children With Autism Spectrum Disorder. A Review of the Research for Parents and Caregivers
Therapies for Children With Autism Spectrum Disorder A Review of the Research for Parents and Caregivers Is This Guide Right for the Child in My Care? Yes, if: The child you care for is 0 to 12 years old
More informationAutism Diagnosis and Management Update. Outline. History 11/1/2013. Autism Diagnosis. Management
Autism Diagnosis and Management Update Cathleen Small, PhD, BCBA-D Developmental Behavioral Pediatrics Maine Medical Partners Outline Autism Diagnosis Brief history New, DSM-5 diagnostic criteria Expressed
More informationValarie Kerschen M.D.
Valarie Kerschen M.D. Greek word meaning self 1940 s Dr Leo Kanner describes classic autism 1940 s Dr Hans Asperger describes Aspergers Syndrome 1960 s Autism theorized to be due to refrigerator mothers
More informationCourse # Understanding Autism
Course # 503 Understanding Autism Disclaimer Slide Understanding Autism Andrea Gregory, MD, FAAP Objectives The learner will understand what Autism Spectrum Disorder encompasses and how it manifests clinically
More informationAUTISM SPECTRUM DISORDER: EVIDENCE BASED TREATMENTS
AUTISM SPECTRUM DISORDER: EVIDENCE BASED TREATMENTS Michelle M. Macias, MD, FAAP Developmental-Behavioral Pediatrics Medical University of South Carolina Ashley Belt, M.Ed., BCBA Board Certified Behavior
More informationAUTISM: THE MIND-BRAIN CONNECTION
AUTISM: THE MIND-BRAIN CONNECTION Ricki Robinson, MD, MPH Co-Director, Descanso Medical Center for Development and Learning - La Canada CA Clinical Professor of Pediatrics, Keck School of Medicine-USC
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationWhat is Autism? -Those with the most severe disability need a lot of help with their daily lives whereas those that are least affected may not.
Autism Summary Autism What is Autism? The Autism Spectrum Disorder (ASD) is a developmental disability that can have significant implications on a child's ability to function and interface with the world
More informationThe Autism Spectrum Disorders: Interventions
The Autism Spectrum Disorders: Interventions Isabelle Rapin Albert Einstein College of Medicine Bronx NY USA No Conflict of Interest Vienna, October 2007 Definitions Three terms I use interchangeably Autism
More informationDisclosures. Autism Society of Wisconsin. Case 2. Case 1. Case 3. Case 4 3/29/2018. Medication treatment for people with Autism Spectrum Disorder
Medication treatment for people with Autism Spectrum Disorder Autism Society of Wisconsin April 20, 2018 Richard P. Barthel, M.D. Disclosures In accordance with the ACCME policy on relevant financial disclosure,
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationAutism Spectrum Disorder: An Update Kathleen A. Koth, D.O.
Autism Spectrum Disorder: An Update Kathleen A. Koth, D.O. Assistant Professor, Child and Adolescent Psychiatry Program Director, Child and Adolescent Psychiatry Fellowship President, Wisconsin Council
More informationNeuren s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome
Neuren (NEU) - ASX Announcement 7 December 2015 Neuren s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome Highlights: Positive top-line results provide a strong rationale
More informationPharmacologic Management of ADHD
Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine
More informationQ&A Summary: Autism Spectrum Disorder (ASD) Part II: Medical Home Care for Children With ASD and Other Developmental Disabilities
Q&A Summary: Autism Spectrum Disorder (ASD) Part II: Medical Home Care for Children With ASD and Other Developmental Disabilities Available On-Demand: optumhealtheducation.com/autism-part-ii-2018 Presenter:
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More informationMedications for Borderline Personality Disorder
Medications for Borderline Personality Disorder Sarah Roff MD, PhD Attending Psychiatrist, DBT Unit, Oregon State Hospital Assistant Professor, Public Psychiatry, OHSU sarah.roff@dhsoha.state.or.us Skills
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationAutism 101: An Introduction for Families
Autism 101: An Introduction for Families Lindsey Miller, ARNP Rachel Montague, Ph.D. June 5, 2012 Overview of Presentation What are Autism Spectrum Disorders? Prevalence & causes Characteristics & related
More information8/23/2017. Chapter 21 Autism Spectrum Disorders. Introduction. Diagnostic Categories within the Autism Spectrum
Chapter 21 Overview Core features of autism spectrum disorders (ASDs) Studies seeking an etiology for ASDs Conditions associated with ASDs Interventions and outcomes Introduction ASDs Class of neurodevelopmental
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationDSM 5 Criteria to Diagnose Autism
DSM 5 Criteria to Diagnose Autism Patient Name Patient Date of Birth Patient Health Plan Provider Name and Credential Date of Exam Only a doctoral level clinician (MD, PhD, and/or PsyD) can complete this
More informationAutism Spectrum Disorder and Mental Health Challenges in Youth
Autism Spectrum Disorder and Mental Health Challenges in Youth Management in the Primary Care Setting February 13, 2016 Rebecca Marshall, MD, MPH Outline DSM V Criteria Comorbidities Behavioral treatments
More informationThe Mental Health and Wellbeing of Children and Adolescents who are affected by Autism and Related Disorders
The Mental Health and Wellbeing of Children and Adolescents who are affected by Autism and Related Disorders Charles Cartwright, M.D Director: YAI Autism Center March 2013 Autism Spectrum Defined by the
More informationDevelopmental Disorders
Pharmacology of Pervasive Developmental Disorders W. David Lohr, M.D. Assistant Professor Child Psychiatry Bingham Child Guidance Center University of Louisville School of Medicine 502-852-1065 wdlohr01@louisville.edu
More informationPsychiatric Disorders in Children and Adolescents D R P E Y M A N B A K H T I A R I A N C H I L D P S Y C H I A T R I S T M A Y 1 4 TH
Psychiatric Disorders in Children and Adolescents D R P E Y M A N B A K H T I A R I A N C H I L D P S Y C H I A T R I S T M A Y 1 4 TH 2 0 1 6 OUTLINE INTRODUCTION ANXIETY DISORDERS MOOD DISORDERS Depressive
More informationCE on SUNDAY Miami, FL May 31, 2009
CE on SUNDAY Miami, FL May 31, 2009 Date: Sunday, May 31, 2009 Time: 9:30 AM 10:45 AM Location: Doubletree Miami Mart/Airport Hotel Title: Speaker(s): Inside the Unknown World of Autism ACPE # 798-000-09-023-L01-P
More informationNeurological Comorbidity
Neurological Comorbidity Ann M Neumeyer, MD Child Neurology Medical Director, Lurie Center for Autism Disclosures Neither I nor my spouse/partner has a relevant financial relationship with a commercial
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationPSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX
A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationDr Keith Ganasen Department of Psychiatry UCT
Dr Keith Ganasen Department of Psychiatry UCT A. Significantly subaverage intellectual functioning: an IQ of approximately 70 or below on an individually administered IQ test B. Concurrent deficits or
More information